ALZN
$1.86
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithiu...
Recent News
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects. ALZN stock is racing ahead of the pack. View the charts here Topline data is expected in the first quarter of 2026. Earlier, the company expected topline results from the first trial by year-end 2025, with follow-up trials in bipolar disorder, major depressive disorder, post-traumatic stress disorder, and Alzheimer's launching th
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore AL001 and its potential to deliver lithium more effectively in the brain than marketed lithium sa
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced its partnership with Mint Labs Inc. d/b/a QMENTA, a medical imaging artificial intelligence company, to support its five upcoming Phase 2 trials of AL001 at Massachusetts General Hospital. QMENTA's cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management. Also Read: EXCLUSIVE: Alzamend Neuro To Start First Phase